KRMD

Over the past six months, KORU Medical Systems' stock experienced a 7.35% decrease in the past month and a year-to-date return of -45.78% as of September 10, 2026, with a 22.03% decline over the last 12 months. On August 5, 2026, the company reported strong Q2 2026 financial results, with net revenues growing 18% year-over-year to $12.0 million, gross profit increasing 20% to $7.8 million (65.1% gross margin), and net income improving 222% to $0.25 million. Despite beating revenue estimates, the stock fell 7.51% after hours due to narrowed full-year 2026 revenue guidance of $47.5 million to $48.5 million, although the gross margin outlook was raised to 62%-64%. Other significant events include the acquisition of a connected monitoring technology asset, a strategic shift in its U.S. oncology market entry involving the withdrawal of a 510(k) application for the FreedomEDGE® with Phesgo®, and entering into a multi-year supply agreement. Insider buying activity was noted, with CEO Adam Kalbermatten acquiring 32,000 shares on September 7, 2026, and 12,500 shares on June 10, 2026, alongside other insider purchases in May 2026. Analyst ratings saw changes, with Weiss Ratings downgrading to a 'sell' on August 19, 2026, Craig Hallum reissuing a 'buy' with a $6.00 price objective on August 6, 2026, and Wall Street Zen cutting its rating to a 'hold' on August 8, 2026. An investigation of the company by Kaskela Law LLC was announced on July 22, 2026.